Insights provides context and perspective about key pharmacy trends and issues

A Thriving Pipeline Expected to Continue Expanding Treatment Options
Drug Pipeline
Our periodic gene therapy report helps payor better understand the potential for these innovative treatments to transform patient care and outcomes More
Briefing
Speciality Pharmacy Pipeline Drugs to Watch | Q4 2020 - Q1 2021
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q4 2020 - Q1 2021 More
Specialty Report
Read the article: Specialty Pharmacy Pipeline Drugs to Watch - Q3-Q4 2020
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q3-Q4 2020 More
Specialty Report
Drug Pipeline
Over the past dozen years, several new treatments have come to market with the first oral preventive expected to be approved in December. Targeted management to help balance access and cost... More
Feature
View article
Drug Pipeline
Updates on the robust gene therapy pipeline from CVS Health pipeline team to help payors stay abreast of this very important emerging category. More
Briefing
Drug Pipeline
After many years of failure, there is hope for potential treatments that could slow disease progression for those with Alzheimer's Disease. If approved, Biogen's aducanumab will... More
Feature
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q2-Q3 2020 More
Specialty Report
Drug Pipeline
New drugs likely to offer patients more options. Key consideration for payors will be effectively balancing high — and rising — price tags with appropriate access. More
Feature
Drug Pipeline
Key drugs to watch for in the specialty pharmacy pipeline Q1-Q2 2020 More
Specialty Report
Drug Pipeline
CVS Health provides an early look at some key Breakthrough Therapies expected to be reviewed by the FDA in 2020 as well as the associated cost implications and expected approval timeframes More
Feature